Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
about
Role of biologics in severe eosinophilic asthma - focus on reslizumabElucidating novel disease mechanisms in severe asthmaEosinophilic bioactivities in severe asthmaNovel strategies for the treatment of asthmaBenralizumab: a unique IL-5 inhibitor for severe asthmaEosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary diseaseProfile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseasesTargeted anti-inflammatory therapeutics in asthma and chronic obstructive lung diseaseUsing Periostin as a Biomarker in the Treatment of AsthmaPersonalized Medicine in AllergyDevelopment of New Therapies for Severe AsthmaManagement of the patient with eosinophilic asthma: a new era beginsReslizumab in the management of poorly controlled asthma: the data so farTherapeutic interventions in severe asthmaClinical profile of patients with adult-onset eosinophilic asthmaReslizumab in Eosinophilic Asthma: A Review.The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps.The immunology of asthma: Asthma phenotypes and their implications for personalized treatment.Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice.Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 productionAnti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis.New and emerging therapies for asthma.Current concepts of severe asthmaTreatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.Antibodies to watch in 2016.Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review.Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.Treatment of severe asthma: entering the era of targeted therapy.Update on reslizumab for eosinophilic asthma.Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy.Emerging interleukin receptor antagonists for the treatment of asthma.Interaction between allergic asthma and atherosclerosis.The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.
P2860
Q26738503-73CCF94E-B0FF-4EE9-9924-4A1023EC3470Q26741488-070F1665-DB5C-4DA8-BA33-D30CF46D92E1Q26744175-AB6D2C13-C891-421B-8A9C-0DE6748D1144Q26748993-9341A3AF-97C1-459C-8FD7-0FBC9E03AC74Q26750711-36EAC45F-B50D-435D-8045-35A6E5907D7CQ26771819-C7696B2A-6B45-47B1-AF96-EA122C99D201Q26778683-15CFC18A-B391-4791-B33D-B6E7F46D9580Q26786229-0A03D8DB-37F7-4DE6-BD54-DF15356D83A2Q28067637-66B2D073-2F9D-4EC7-B489-58AFF920FF24Q28073074-E9E75ADB-DBC4-411A-B5CB-69785F5D2593Q28077546-DED05F5E-8F3A-4406-A0E7-CDC1CA827551Q28078191-998EFEBC-2429-4658-8B95-41D89E459802Q28078290-95B12CBD-4CE2-4D2A-A2A5-7147C38119D7Q28079238-D4A3ABF3-709A-4DFE-ABD6-66463B2C931FQ28596640-37089716-7879-4981-81A4-F20BC7D70BA1Q30234750-29B8C71C-E22F-4866-A589-4E85F6472A1AQ30248905-106EE163-0E62-4424-A1FF-0F456D11709CQ30252446-ECEE31C7-ABD9-41BF-94EB-997D96D995D4Q30276175-07937C9C-04F7-43CF-850E-E5E8F80BDD70Q30276354-D994E383-ADB3-48D2-8B5C-72E9738F998FQ31038671-DDEBD1CA-0668-4A45-863A-E58974DC4653Q33581536-CA44C36C-D13A-4167-8401-DD0F1B930866Q33786076-20EC94ED-C3B2-4815-8D58-9C2171EC7FF3Q33871749-88FC52F5-1A35-4AC2-B3F7-FCB87555E6FAQ33918803-D1203A50-E452-4FE2-8EA7-BB031E4D2E25Q36146267-D3686042-3054-4C74-BA90-6927BCEB64CAQ36201117-FB0CB151-220C-4864-92C5-0DFFBA79E153Q36409355-F2CA3D2E-E8A5-4525-8A54-EEE2D75F806FQ37042266-2808838A-C2A5-4482-9A82-88F4113D068AQ37062124-2753884E-70E8-445B-8D78-2F7290B932EBQ37138505-877278AE-997F-4111-851D-541363E093A7Q37645627-8B282600-14D0-4DD1-9D63-6AA315B86092Q37708016-B4FF1D16-3551-4184-B0DC-113B88356723Q38578918-F971E5DD-E1C9-4D78-B043-1C6E9604573AQ38587334-975F3002-9BF0-4C27-8BB2-4C22176DCFF1Q38599656-7920AA2A-FB7E-45A0-A615-EB31E7EDA940Q38606180-6BC508AA-5EA3-4071-83BB-1FAA61C051F1Q38638355-D547A06E-0115-401C-9CB2-F6C94E6BC95CQ38648016-63045168-1372-4B50-82EE-C5282AB79B51Q38649675-4A8E8EF0-895E-45D9-9097-3BC41DECE3C8
P2860
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Reslizumab for inadequately co ...... bo-controlled, phase 3 trials.
@en
type
label
Reslizumab for inadequately co ...... bo-controlled, phase 3 trials.
@en
prefLabel
Reslizumab for inadequately co ...... bo-controlled, phase 3 trials.
@en
P2093
P921
P1476
Reslizumab for inadequately co ...... bo-controlled, phase 3 trials.
@en
P2093
Christopher O'Brien
Eric D Bateman
James Zangrilli
Jorge F Maspero
Kevin Murphy
Mario Castro
Michael E Wechsler
Philip Bardin
Stephanie Korn
P304
P356
10.1016/S2213-2600(15)00042-9
P577
2015-02-23T00:00:00Z